SPARC Antibody [Biotin]

MG-63 cells were stained with Goat Anti-Human SPARC Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF941, filled histogram) or isotype control antibody (Catalog # BAF108, open histogram) followed by Streptavidin-Allophycocyanin (Catalog # F0050). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with Flow Cytometry Permeabilization/Wash Buffer I (Catalog # FC005). View our protocol for Staining Intracellular Molecules.

• Reactivity: Hu
• Applications: WB, Flow
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

SPARC Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human SPARC/Osteonectin
  Ala18-Ile303
  Accession # P09486
• Specificity: Detects human SPARC in Western blots. In Western blots, less than 1% cross-reactivity with recombinant mouse SPARC is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: SPARC
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Intracellular Staining by Flow Cytometry 0.25 ug/10^6 cells
  • Western Blot 0.1 ug/mL
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SPARC Antibody [Biotin]

• Basement-membrane protein 40
• BM-40
• ONcysteine-rich protein
• Osteonectin
• Secreted protein acidic and rich in cysteine
• secreted protein, acidic, cysteine-rich (osteonectin)
• SPARC

Background

SPARC, an acronym for “secreted protein, acidic and rich in cysteine”, is also known as osteonectin or BM-40 (1-5). It is the founding member of a family of secreted matricellular proteins with similar domain structure. The 286 amino acid (aa), 43 kDa protein contains an N-terminal acidic region that binds calcium, a follistatin domain that contains Kazal-like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs (1-5). Crystal structure modeling shows that residues implicated in cell binding, inhibition of cell spreading, and disassembly of focal adhesions cluster on one face of SPARC, while a collagen binding epitope and an N-glycosylation site are opposite this face (6). SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling (3, 7). SPARC shows context-specific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation (3-5). For endothelial cells, SPARC disrupts focal adhesions and binds and sequesters PDGF and VEGF (3-5). SPARC is abundantly expressed in bone, where it promotes osteoblast differentiation and inhibits adipogenesis (5, 8). SPARC is potentially cleaved by metalloproteinases, producing an angiogenic peptide that includes the copper-binding sequence KGHK (7). Paradoxically, SPARC is highly expressed in many tumor types undergoing an endothelial to mesenchymal transistion; its expression, however, mainly decreases the likelihood of metastasis and confers sensitivity to chemotherapy and radiation (4, 9-11). Stabilin-1, which is expressed on alternately activated macrophages, is the first SPARC receptor to be identified. It binds the SPARC EC domain and mediates endocytosis for degradation (12). Mature human SPARC shows 92%, 92%, 97%, 99%, 96%, and 85% aa identity with mouse, rat, canine, bovine, porcine, and chick SPARC, respectively.

1. Lankat-Buttgereit, B. et al. (1988) FEBS Lett. 236:352.
2. Sweetwyne, M.T. et al. (2004) J. Histochem. Cytochem. 52:723.
3. Sage, H. et al. (1989) J. Cell Biol. 109:341.
4. Framson, P.E. and E.H. Sage (2004) J. Cell. Biochem. 92:679.
5. Alford, A.I. and K.D. Hankenson (2006) Bone 38:749.
6. Hohenester, E et al. (1997) EMBO J. 16:3778.
7. Sage, E.H. et al. (2003) J. Biol. Chem. 278:37849.
8. Delany, A.M. et al. (2003) Endocrinology 144:2588.
9. Robert, G. et al. (2006) Cancer Res. 66:7516.
10. Koblinski, J.E. et al. (2005) Cancer Res. 65:7370.
11. Tai, I.T. et al. (2005) J. Clin. Invest. 115:1492.
12. Kzhyshkowska, J. et al. (2006) J. Immunol. 176:5825.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for SPARC Antibody (BAF941)(2)

Publications using BAF941

• Xu , Lu, Ping , Fan, Yin , Jinhua, Xiao , Xinhua, Xiang , Hongding, Ballantyne , Christie, Wu , Huaizhu, Li , Ming Elevated plasma SPARC levels are associated with insulin resistance, dyslipidemia, and inflammation in gestational diabetes mellitus. PLoS ONE, 2013-12-09;8(12):e81615. 2013-12-09 [PMID: 24349098] (ELISA Development, Human)
• Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells. Glia, 2006-06-01;53(8):845-57. 2006-06-01 [PMID: 16586492] (ELISA Development, Human)

Bioinformatics

• Gene Symbol: SPARC
• Uniprot:
  • P09486()